Cardiolipin

Cardiolipin (CL) is the signature diphosphatidylglycerol phospholipid of the inner mitochondrial membrane (IMM) - a unique cone-shaped molecule with four acyl chains and two phosphate groups that is absolutely required for respiratory supercomplex assembly, cristae architecture, ATP synthase stability, and the initiation of apoptotic signaling. In mammalian heart and skeletal muscle the predominant form is tetralinoleoyl CL (all four chains are linoleoyl, C18:2; molecular formula C₈₁H₁₄₀O₁₇P₂). Mutations in tafazzin (the CL reacylase) cause Barth syndrome - X-linked cardiomyopathy, neutropenia, and growth retardation from abnormal CL acyl chain remodeling. Elamipretide (SS-31), a mitochondria-targeted peptide that binds CL, received FDA approval in September 2025 for Barth syndrome. This card defines the scaffold space for mitochondria-targeted peptides, cardioprotective agents, and antimicrobial CL-targeting scaffolds.

CL is synthesized exclusively in the IMM: cardiolipin synthase (CLS) condenses CDP-DAG and phosphatidylglycerol → nascent CL → tafazzin-mediated deacylation/reacylation generates the mature tetralinoleoyl species with optimal biophysical properties (high negative charge, −2 at pH 7.4; conical geometry that drives membrane curvature and non-bilayer hexagonal phases). CL constitutes 15–20% of IMM phospholipids. Functions: (1) stabilizes respiratory chain complexes I–IV and ATP synthase - CL depletion abolishes supercomplex assembly and sharply reduces electron transfer efficiency and proton-motive force; (2) supports mitochondrial fusion/fission dynamics and protein import through the TIM23 translocase; (3) facilitates mitophagy via Beclin-1 recruitment; (4) during apoptosis, cytochrome c peroxidase activity on CL generates oxidized CL species → cytochrome c detaches from IMM → released into cytosol → caspase-9 activation. In bacteria (Gram-positive organisms including Staphylococcus, Bacillus, Enterococcus), CL analogs appear in the plasma membrane where they cluster at sites of negative curvature (cell poles, division septa) - explaining why CL-targeting cationic antimicrobial peptides kill Gram-positives preferentially.

Elamipretide (SS-31; D-Arg-dimethylTyr-Lys-Phe-NH₂, 4 aa) is FDA-approved (September 2025) for Barth syndrome as an SC injection - it crosses the outer mitochondrial membrane, accumulates in the IMM by electrostatic interaction with CL's negative charge, and prevents CL peroxidation, thereby stabilizing cytochrome c–CL interaction and restoring respiratory supercomplex function. MTP-131 clinical trials also demonstrated improvement in renal function in acute kidney injury and heart failure with reduced ejection fraction. For peptide research, the tractable recipes are: SS-31 (elamipretide) analogs with aromatic position 2 substitutions (Tyr→Trp→naphthylalanine) to tune CL-binding affinity and antioxidant potency; mitochondria-targeted sequence (MTS)–peptide conjugates that use the natural preprotein import machinery to deliver payloads to the IMM; cationic antimicrobial peptides with engineered CL specificity (using the bacterial CL geometry selectivity filter - patches of Lys/Arg flanking a central hydrophobic face of ~8–12 residues) for Gram-positive infections; and cyclic CL-binding peptide probes with fluorescent or radiolabeled tags for imaging oxidized CL exposure on the outer mitochondrial membrane during early apoptosis in tumor detection.